Omeprazole and visual disorders: Seeing alternatives

M. Lindquist, M. Pettersson, I. Ralph Edwards, J. Sanderson, N. Taylor, P. Fletcher, J. Schou, Frederick (Fritz) Fraunfelder

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

In the WHO data base, visual disorders reported spontaneously with omeprazole, ranitidine and cimetidine, are very rare in the context of the widespread use of these drugs. There is a maximum reporting rate of severe visual impairment possibly ascribed to i.v. omeprazole of 0.94 reports per million treatment days in one year and in one country, Germany. This gives the worst quantitative case scenario for omeprazole by a single route of administration, to be compared with the worldwide reporting rate of all severe visual disorders by all routes of administration - 0.008 reports per million treatment days. Moreover, the reported visual abnormalities have a varied pathophysiological aetiology and their number increased in Germany after the first signal was raised in that country. Thus, apart from a direct causal relationship, solicited reporting artifact is one alternate plausible explanation for the apparent excess of cases of visual disturbance to omeprazole compared with cimetidine and ranitidine. That reporting rates of clinical events on newly marketed drugs are generally higher than with older drugs is a second factor for higher reporting rates with omeprazole. Vasculitis has been suggested as an aetiological factor, but the even lower reporting rate of this reaction makes this an unlikely hypothesis without any other supporting evidence. The authors are unaware of any drug that has caused a vasculitis solely affecting the eye. Information on the prevalence of relevant visual disorders in the community would have been of considerable help in interpreting this signal, and a case control study of visual events in relationship to severe illness would be of public health interest, since no data seems to exist concerning this.

Original languageEnglish (US)
Pages (from-to)27-32
Number of pages6
JournalPharmacoepidemiology and Drug Safety
Volume5
Issue number1
DOIs
StatePublished - Jan 1996

Fingerprint

Omeprazole
Vision Disorders
Ranitidine
Cimetidine
Vasculitis
Pharmaceutical Preparations
Germany
Artifacts
Case-Control Studies
Public Health
Databases

Keywords

  • Adverse events
  • Cimetidine
  • Omeprazole
  • Ranitidine
  • Vision

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Omeprazole and visual disorders : Seeing alternatives. / Lindquist, M.; Pettersson, M.; Ralph Edwards, I.; Sanderson, J.; Taylor, N.; Fletcher, P.; Schou, J.; Fraunfelder, Frederick (Fritz).

In: Pharmacoepidemiology and Drug Safety, Vol. 5, No. 1, 01.1996, p. 27-32.

Research output: Contribution to journalArticle

Lindquist, M, Pettersson, M, Ralph Edwards, I, Sanderson, J, Taylor, N, Fletcher, P, Schou, J & Fraunfelder, FF 1996, 'Omeprazole and visual disorders: Seeing alternatives', Pharmacoepidemiology and Drug Safety, vol. 5, no. 1, pp. 27-32. https://doi.org/10.1002/(SICI)1099-1557(199601)5:1<27::AID-PDS199>3.0.CO;2-1
Lindquist M, Pettersson M, Ralph Edwards I, Sanderson J, Taylor N, Fletcher P et al. Omeprazole and visual disorders: Seeing alternatives. Pharmacoepidemiology and Drug Safety. 1996 Jan;5(1):27-32. https://doi.org/10.1002/(SICI)1099-1557(199601)5:1<27::AID-PDS199>3.0.CO;2-1
Lindquist, M. ; Pettersson, M. ; Ralph Edwards, I. ; Sanderson, J. ; Taylor, N. ; Fletcher, P. ; Schou, J. ; Fraunfelder, Frederick (Fritz). / Omeprazole and visual disorders : Seeing alternatives. In: Pharmacoepidemiology and Drug Safety. 1996 ; Vol. 5, No. 1. pp. 27-32.
@article{fe8fb084b64247e4ac765c3fff3c0bc3,
title = "Omeprazole and visual disorders: Seeing alternatives",
abstract = "In the WHO data base, visual disorders reported spontaneously with omeprazole, ranitidine and cimetidine, are very rare in the context of the widespread use of these drugs. There is a maximum reporting rate of severe visual impairment possibly ascribed to i.v. omeprazole of 0.94 reports per million treatment days in one year and in one country, Germany. This gives the worst quantitative case scenario for omeprazole by a single route of administration, to be compared with the worldwide reporting rate of all severe visual disorders by all routes of administration - 0.008 reports per million treatment days. Moreover, the reported visual abnormalities have a varied pathophysiological aetiology and their number increased in Germany after the first signal was raised in that country. Thus, apart from a direct causal relationship, solicited reporting artifact is one alternate plausible explanation for the apparent excess of cases of visual disturbance to omeprazole compared with cimetidine and ranitidine. That reporting rates of clinical events on newly marketed drugs are generally higher than with older drugs is a second factor for higher reporting rates with omeprazole. Vasculitis has been suggested as an aetiological factor, but the even lower reporting rate of this reaction makes this an unlikely hypothesis without any other supporting evidence. The authors are unaware of any drug that has caused a vasculitis solely affecting the eye. Information on the prevalence of relevant visual disorders in the community would have been of considerable help in interpreting this signal, and a case control study of visual events in relationship to severe illness would be of public health interest, since no data seems to exist concerning this.",
keywords = "Adverse events, Cimetidine, Omeprazole, Ranitidine, Vision",
author = "M. Lindquist and M. Pettersson and {Ralph Edwards}, I. and J. Sanderson and N. Taylor and P. Fletcher and J. Schou and Fraunfelder, {Frederick (Fritz)}",
year = "1996",
month = "1",
doi = "10.1002/(SICI)1099-1557(199601)5:1<27::AID-PDS199>3.0.CO;2-1",
language = "English (US)",
volume = "5",
pages = "27--32",
journal = "Pharmacoepidemiology and Drug Safety",
issn = "1053-8569",
publisher = "John Wiley and Sons Ltd",
number = "1",

}

TY - JOUR

T1 - Omeprazole and visual disorders

T2 - Seeing alternatives

AU - Lindquist, M.

AU - Pettersson, M.

AU - Ralph Edwards, I.

AU - Sanderson, J.

AU - Taylor, N.

AU - Fletcher, P.

AU - Schou, J.

AU - Fraunfelder, Frederick (Fritz)

PY - 1996/1

Y1 - 1996/1

N2 - In the WHO data base, visual disorders reported spontaneously with omeprazole, ranitidine and cimetidine, are very rare in the context of the widespread use of these drugs. There is a maximum reporting rate of severe visual impairment possibly ascribed to i.v. omeprazole of 0.94 reports per million treatment days in one year and in one country, Germany. This gives the worst quantitative case scenario for omeprazole by a single route of administration, to be compared with the worldwide reporting rate of all severe visual disorders by all routes of administration - 0.008 reports per million treatment days. Moreover, the reported visual abnormalities have a varied pathophysiological aetiology and their number increased in Germany after the first signal was raised in that country. Thus, apart from a direct causal relationship, solicited reporting artifact is one alternate plausible explanation for the apparent excess of cases of visual disturbance to omeprazole compared with cimetidine and ranitidine. That reporting rates of clinical events on newly marketed drugs are generally higher than with older drugs is a second factor for higher reporting rates with omeprazole. Vasculitis has been suggested as an aetiological factor, but the even lower reporting rate of this reaction makes this an unlikely hypothesis without any other supporting evidence. The authors are unaware of any drug that has caused a vasculitis solely affecting the eye. Information on the prevalence of relevant visual disorders in the community would have been of considerable help in interpreting this signal, and a case control study of visual events in relationship to severe illness would be of public health interest, since no data seems to exist concerning this.

AB - In the WHO data base, visual disorders reported spontaneously with omeprazole, ranitidine and cimetidine, are very rare in the context of the widespread use of these drugs. There is a maximum reporting rate of severe visual impairment possibly ascribed to i.v. omeprazole of 0.94 reports per million treatment days in one year and in one country, Germany. This gives the worst quantitative case scenario for omeprazole by a single route of administration, to be compared with the worldwide reporting rate of all severe visual disorders by all routes of administration - 0.008 reports per million treatment days. Moreover, the reported visual abnormalities have a varied pathophysiological aetiology and their number increased in Germany after the first signal was raised in that country. Thus, apart from a direct causal relationship, solicited reporting artifact is one alternate plausible explanation for the apparent excess of cases of visual disturbance to omeprazole compared with cimetidine and ranitidine. That reporting rates of clinical events on newly marketed drugs are generally higher than with older drugs is a second factor for higher reporting rates with omeprazole. Vasculitis has been suggested as an aetiological factor, but the even lower reporting rate of this reaction makes this an unlikely hypothesis without any other supporting evidence. The authors are unaware of any drug that has caused a vasculitis solely affecting the eye. Information on the prevalence of relevant visual disorders in the community would have been of considerable help in interpreting this signal, and a case control study of visual events in relationship to severe illness would be of public health interest, since no data seems to exist concerning this.

KW - Adverse events

KW - Cimetidine

KW - Omeprazole

KW - Ranitidine

KW - Vision

UR - http://www.scopus.com/inward/record.url?scp=0029995011&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029995011&partnerID=8YFLogxK

U2 - 10.1002/(SICI)1099-1557(199601)5:1<27::AID-PDS199>3.0.CO;2-1

DO - 10.1002/(SICI)1099-1557(199601)5:1<27::AID-PDS199>3.0.CO;2-1

M3 - Article

C2 - 15088274

AN - SCOPUS:0029995011

VL - 5

SP - 27

EP - 32

JO - Pharmacoepidemiology and Drug Safety

JF - Pharmacoepidemiology and Drug Safety

SN - 1053-8569

IS - 1

ER -